H.C. Wainwright raised the firm’s price target on Lineage Cell Therapeutics (LCTX) to $9 from $7 and keeps a Buy rating on the shares. The firm says “we are in a highly critical timeframe” for Lineage’s investment case and this is based on the Phase 2a data out of Roche for OpRegen. The firm believes OpRegen is “likely to get back into a bright spotlight soon” as Roche data “could come at any time.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LCTX:
- Lineage Therap Announces $66 Million Direct Offering
- Lineage Cell price target lowered to $2 from $3 at D. Boral Capital
- Lineage Cell Therapeutics initiated with a Buy at D. Boral Capital
- Lineage Cell Therapeutics Reports Q3 2024 Highlights
- Lineage Cell Therapeutics reports Q3 EPS (2c), consensus (3c)